Navigation Links
C8 MediSensors Closes $19 million Preferred Stock Financing

SAN JOSE, Calif., June 11, 2012 /PRNewswire/ -- C8 MediSensors, Inc. (, the leading company developing noninvasive continuous glucose monitoring for people with diabetes, announced today that it has raised an incremental $19 million through the sale of Preferred C-1 stock.


This additional round of funding helps C8 MediSensors prepare for its upcoming product launch in Europe. C8 MediSensors' leading investors participated in this funding round.

Nearly 300 million people worldwide suffer from diabetes. C8 MediSensors has pioneered the use of light, specifically Raman spectroscopy, to measure glucose non-invasively with a continuous glucose monitor that is worn around the abdomen and sends readings to the user's smartphone. 

C8 MediSensors' CEO, Paul Zygielbaum, himself a person with diabetes, commented: "Better diabetes management requires better glucose visibility to the patient. You can't control what you can't see. After years of research, development and clinical testing, we are thrilled to be on the verge of introducing our optical glucose monitor, which is designed to provide people like me with continuous visibility into their glucose levels throughout the day."

C8 MediSensors has filed for CE Mark approval and plans to introduce their optical continuous glucose monitor in Europe in 2H 2012, pending regulatory approval.

About C8 MediSensors

Headquartered in San Jose CA, C8 MediSensors' breakthrough patent-protected technology is being developed to give people with diabetes an adjunctive, continuous view of their glucose levels.

This document contains forward-looking statements. Any statements contained in this document that are not statements of historical fact may be deemed to be forward- looking statements, including, without limitation, statements relating to C8 MediSensors' anticipated product sales and financing needs. These forward-looking statements are based upon C8 MediSensors' current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with market conditions, customer demand for the product, and risks and uncertainties associated with C8 MediSensors' business and finances in general. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. C8 MediSensors does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

C8 MediSensors, Inc. 6375 San Ignacio Avenue, San Jose, CA 95119, USA

SOURCE C8 MediSensors, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Closes Cameron Health Acquisition
2. Stereotaxis Closes $18.5 Million Private Placement Financings
3. Independa Closes Convertible Note Funding at $2.35 Million
4. Novelos Therapeutics Prices $5.4 Million Public Offering
5. First sales of DIFICLIRâ„¢ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
6. InnoPharma Inc. Raises $8 Million in Venture Debt
7. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
8. Software Pioneer Leaves $10 Million Bequest To Five Leading Non-profits In Health And Drug Policy Reform
9. AssureRx Health Raises $12.5 Million Series C Financing
10. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
11. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
Post Your Comments:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
Breaking Medicine News(10 mins):